Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Glenmark Pharmaceuticals (GNP IN)
Watchlist
138
Analysis
Health Care
•
India
Glenmark Pharmaceuticals Ltd., is a pharmaceutical company. The Company develops generic drugs for inflammation, metabolic disorders, and pain.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
MSCI World Index
•
15 Nov 2018 21:39
Global Markets Outlook: Maintain Defensive Posture
Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term...
Vermilion Research
Follow
545 Views
Share
bullish
•
MSCI Emerging Markets Index
•
05 Nov 2018 22:59
EM Strategy: Brazil Breaking Out, EM Energy Remains Attractive
While the MSCI EM index remains in a well-defined downtrend, and we continue to recommend selectivity, we highlight several investable themes and...
Vermilion Research
Follow
467 Views
Share
bullish
•
361 Degrees International
•
02 Nov 2018 00:00
Asia HY Monthly - Corporate Governance In Chinese Companies - Lucror Analytics
In this month’s “In-Focus” section, we discuss Corporate Governance in Chinese Companies. Specifically, we highlight: [1] the nascent development...
Lucror Analytics
Follow
65 Views
Share
bearish
•
Glenmark Pharmaceuticals
•
12 Oct 2018 09:26
Glenmark Pharmaceuticals: Attempt Out of Generic
We initiate our coverage on Glenmark Pharmaceuticals (GNP IN) (“Glenmark”)’s GNPIN 4.5% 8/21s (BB-/BB by S&P and Fitch, respectively) with a...
Bondcritic
Follow
427 Views
Share
bullish
•
MSCI Emerging Markets Index
•
26 Aug 2018 23:31
EM Strategy: Remain Overweight India
In this report we provide a synopsis of EM markets. We also scour the EM universe for attractive and actionable opportunities, highlighting...
Vermilion Research
Follow
426 Views
Share
First
Previous
22
23
24
25
26
27
28
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.36.1
x